Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1

Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1

Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1

Evaxion Hørsholn, Denmark The new data demonstrates the potential to improve control of acute infection, latency, and viral reactivation, further supporting the concept behind EVX-V1 EVX-V1 is a next-generation, multi-component vaccine program combining novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens Data presented today in poster presentation at the International Herpesvirus Workshop 2026 taking place in Montreal, Canada COPENHAGEN, Denmark, July 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, presents new data further supporting the multi-component concept of its cytomegalovirus (CMV) vaccine program EVX-V1. Data is presented today in a poster session at the International Herpesvirus Workshop (IHW) 2026 taking place in Montreal, Canada. EVX-V1 is a next-generation, multi-component CMV vaccine program designed with AI-Immunology™. It combines novel protective B-cell antigens and T-cell epitopes complemented by known optimized structural B-cell antigens This broader multi-targeted strategy is expected to strengthen the protective potential of a future vaccine. The concept represents a scalable strategy for rational vaccine development across other herpesviruses. “We are excited by the new data which will guide the selection of antigens for a broadly protective CMV vaccine candidate and as such represent an important step forward for the EVX-V1 program. CMV remains a major clinical challenge, causing severe disease in immunocompromised individuals and infants, yet no licensed vaccine exists. EVX-V1 holds the potential to transform the future CMV treatment landscape,” says Birgitte Rønø, CSO and COO of Evaxi...